Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute, Boston, MA, discusses tools used to assess frailty in patients with multiple myeloma, such as the International Myeloma Working Group (IMWG) frailty score and the Charlson Comorbidity Index (CCI), and further comments on the importance of incorporating these tools into clinical trial design. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.